Pharmafile Logo
Pharmafocus logo
Advanced Search

hepatitis C

Showing 5 posts of 65 posts found.

Telaprevir to be added to standard hep C therapy

March 27, 2011
Research and Development, Sales and Marketing hepatitis C, telaprevir

Telaprevir – currently being co-developed by Vertex, Johnson & Johnson and Mitsubishi Tanabe  – will become part of a standard …

News

J&J hepatitis C drug begins phase III trials

February 23, 2011
Research and Development J&J, JJ, Johnson and Johnson, TMC435, Tibotec, hepatitis, hepatitis C

Johnson & Johnson has begun late stage trials of hepatitis C drug TMC435 as a first line treatment for the …

News

Regulators fast-track Merck’s hepatitis C drug boceprevir

January 7, 2011
Sales and Marketing Merck & Co, boceprevir, hepatitis C, telaprevir

Merck’s new oral hepatitis C drug boceprevir will receive fast track reviews from both the FDA and the EMA after …

News

New hepatitis C drug offers cure for more patients

December 17, 2010
Research and Development, Sales and Marketing HCV, Janssen, hepatitis C, liver disease, telaprevir

A new treatment from Janssen which could help cure many more patients with hepatitis C has been submitted in Europe. …

News

Abbott hep C drug ABT-450/r impresses in mid-stage trial

November 2, 2010
Research and Development ABT-450/r, Abbott, Abbott Laboratories, American Liver Disease congress, Enanta Pharmaceuticals, Norvir, hepatitis C

Mid-stage trial results of Abbott Laboratories’ oral hepatitis C drug ABT-450/r have impressed at the American Liver Disease congress. The …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026